MONARCC
The aim of this study is to investigate the activity of anti-EGFR monotherapy, or combined with infusional 5FU, in a molecularly selected, elderly patient population with metastatic colorectal cancer.
Metastatic colorectal cancer is a disease of the elderly. Anti-EGFR antibodies have not been well studied in an elderly patient population unsuited to combination chemotherapy. The median age in trials involving these agents is 60-65 years. As a result there is an opportunity to investigate the activity of anti-EGFR monotherapy, or combined with “light” chemotherapy in a molecularly selected, hitherto under-investigated but prevalent patient population.
Trial Status
Open
Cancer Type
Colorectal Cancer
If you think this trial is relevant to your situation, please contact your Cancer Specialist to discuss further.
Aim
The aim of this study is to investigate the activity of anti-EGFR monotherapy, or combined with infusional 5FU, in a molecularly selected, elderly patient population with metastatic colorectal cancer.
Summary
Metastatic colorectal cancer is a disease of the elderly. Anti-EGFR antibodies have not been well studied in an elderly patient population unsuited to combination chemotherapy. The median age in trials involving these agents is 60-65 years. As a result there is an opportunity to investigate the activity of anti-EGFR monotherapy, or combined with “light” chemotherapy in a molecularly selected, hitherto under-investigated but prevalent patient population.
Participating Centres
Trial Status
Open
Cancer Type
Colorectal Cancer
If you think this clinical trial may be relevant to your patient or to discuss further, please contact the Clinical Trial team.
Protocol Title
A randomised phase 2 study of panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer
Aim
The aim of this study is to investigate the activity of anti-EGFR monotherapy, or combined with infusional 5FU, in a molecularly selected, elderly patient population with metastatic colorectal cancer.
Background
Metastatic colorectal cancer is a disease of the elderly. Anti-EGFR antibodies have not been well studied in an elderly patient population unsuited to combination chemotherapy. The median age in trials involving these agents is 60-65 years. As a result there is an opportunity to investigate the activity of anti-EGFR monotherapy, or combined with “light” chemotherapy in a molecularly selected, hitherto under-investigated but prevalent patient population.
CLINICAL TRIAL DESIGN
A prospective randomised phase 2 study to assess the activity of panitumumab alone versus panitumumab plus 5FU as first line treatment for RAS wild type elderly patients with metastatic colorectal cancer.
Patients Recruited
Click to access the table and view recruitment data on all AGITG open trials:
Participating Centres
Contact Email
monarcc@ctc.usyd.edu.auPrincipal Investigator
Dr Matthew Burge
More Information
More detailed information available online at the Australian New Zealand Clinical Trial Registry (ANZCTR) here
Funding
AGITG Innovation Fund ($100,000)
Alan Bishop Fund ($20,000)
Changing outcomes for people with gastro-intestinal cancer